Virpax Pharmaceuticals doubles on plans to develop spray against viruses

Virpax Pharmaceuticals

17/08/2021 15:28

** Pain drug developer's shares  VRPX.O  double in value to
touch a record high of $8.37 
    ** Co says the U.S. FDA has indicated that co can pursue
approval of its product MMS019 as a non-prescription drug to be
used an intranasal protective to reduce spread of viruses
 urn:newsml:reuters.com:*:nBw11VJ7Xa
    ** Co says has engaged contract researcher Syneos Health
 SYNH.O  to assist with clinical trials 
    ** The spray is under development for use as an anti-viral
barrier product
    ** Over 25 mln shares traded, more than 73x times their
25-day moving avg
    ** Shares have risen ~37% since their IPO in February

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24))